<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2596">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335084</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-042</org_study_id>
    <nct_id>NCT04335084</nct_id>
  </id_info>
  <brief_title>A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</brief_title>
  <acronym>HELPCOVID-19</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSCS CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II interventional study testing whether treatment with hydroxychloroquine,
      Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will take a regimen of hydroxychloroquine, vitamin C, vitamin D, and
      Zinc to test if this combination can prevent COVID-19. Treatment with hydroxychlorquine will
      last 1 day. Treatment with vitamin C, vitamin D, and and zinc will last 12 weeks. The study
      will last 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study will focus on medical workers who at elevated risk of COVID-19 due to exposure to positive patients in the Emergency Department or Intensive Care Unit</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of COVID-19 symptoms as recorded in a daily diary</measure>
    <time_frame>24 weeks</time_frame>
    <description>Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as determined by presence or absence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess the presence or absence of side effects (graded 1-5), and whether they are tolerable (grade 1-2). AE and SAE will be recorded.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <condition>Coronavirus Infection</condition>
  <condition>Sars-CoV2</condition>
  <condition>Corona Virus Infection</condition>
  <condition>COVID</condition>
  <condition>Coronavirus</condition>
  <condition>Coronavirus-19</condition>
  <condition>Coronavirus 19</condition>
  <arm_group>
    <arm_group_label>Medical Workers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Medical workers how are exposed to COVID-19 and as such are at a higher risk for infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Prophylaxis treatment for COVID-19</description>
    <arm_group_label>Medical Workers</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Prophylaxis treatment for COVID-19</description>
    <arm_group_label>Medical Workers</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Prophylaxis treatment for COVID-19</description>
    <arm_group_label>Medical Workers</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Prophylaxis treatment for COVID-19</description>
    <arm_group_label>Medical Workers</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent, provided electronically via the EDC, demonstrating the subject
             understands the procedures required for the study and the purpose of the study

          2. Male or female patients 18 years of age or older that are considered to be high-risk
             individuals.

             a. High-risk individuals are defined as all health care workers in hospitals, clinics,
             and emergency rooms, and medical facilities.

          3. Subjects must agree to practice at least two highly effective methods of birth control
             for the duration of the study This includes condoms with spermicide, oral birth
             control pills, contraceptive implants, intra-uterine devices, or diaphragms. At least
             one of these must be a barrier method. Subjects not of reproductive potential will be
             exempt (e.g. post-menopausal, surgically sterilized)

        Exclusion Criteria:

          1. Refusal to provide informed consent

          2. Any previous positive test for COVID-19 by RT-PCR

          3. Symptomatic for COVID-19

          4. Diarrhea prior to the start of treatment

          5. Type I or II diabetes

          6. Atherosclerotic Coronary Artery Disease

          7. Any contraindication for treatment with hydroxychloroquine including:

               1. Hypoglycemia

               2. G6PD deficiency

               3. Porphyria

               4. Anemia

               5. Neutropenia

               6. Alcoholism

               7. Myasthenia Gravis

               8. Skeletal muscle disorder

               9. Maculopathy

              10. Changes in the visual field

              11. Liver disease, with ALT/AST &gt; 2.5 upper limit normal and total bilirubin &gt;2.5
                  upper limit normal

              12. Psoriasis

              13. Any contraindicated medications found in Appendix 2

          8. Any comorbidities which, in the opinion of the investigator, constitute health risk
             for the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>805-339-0549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>217-494-6692</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>drsabinehazan@progenabiome.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>805-339-0549</phone>
      <email>jordan@progenabiome.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Banjanac M, Munić Kos V, Nujić K, Vrančić M, Belamarić D, Crnković S, Hlevnjak M, Eraković Haber V. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res. 2012 Oct;66(4):357-62. doi: 10.1016/j.phrs.2012.06.011. Epub 2012 Jul 3.</citation>
    <PMID>22766077</PMID>
  </reference>
  <reference>
    <citation>Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.</citation>
    <PMID>32173110</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.</citation>
    <PMID>32052466</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

